Israel Englander’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.73M Sell
1,834,762
-777,515
-30% -$2.59M ﹤0.01% 2707
2026
Q1
$8.02M Buy
2,612,277
+1,116,438
+75% +$4.31M ﹤0.01% 2400
2025
Q4
$6.12M Buy
+1,495,839
New +$7.41M ﹤0.01% 2787
2025
Q3
Sell
-739,408
Closed -$3.74M 6406
2025
Q2
$3.74M Buy
739,408
+237,300
+47% +$1.17M ﹤0.01% 3277
2025
Q1
$2.66M Buy
502,108
+473,798
+1,674% +$3.45M ﹤0.01% 3507
2024
Q4
$191K Sell
28,310
-10,473
-27% -$70.4K ﹤0.01% 5324
2024
Q3
$256K Buy
+38,783
New +$278K ﹤0.01% 5302
2024
Q2
Sell
-11,077
Closed -$96.6K 6448
2024
Q1
$110K Buy
+11,077
New +$123K ﹤0.01% 5552
2023
Q4
Sell
-658,355
Closed -$5.04M 6470
2023
Q3
$5.04M Buy
+658,355
New +$6.57M ﹤0.01% 2673
2023
Q2
Sell
-646,610
Closed -$4.31M 6612
2023
Q1
$4.31M Sell
646,610
-48,763
-7% -$387K ﹤0.01% 2740
2022
Q4
$5.36M Buy
695,373
+455,977
+190% +$4.47M ﹤0.01% 2753
2022
Q3
$2.55M Sell
239,396
-143,778
-38% -$1.46M ﹤0.01% 3527
2022
Q2
$3.12M Sell
383,174
-111,978
-23% -$749K ﹤0.01% 3254
2022
Q1
$3.54M Buy
495,152
+461,323
+1,364% +$4.9M ﹤0.01% 3315
2021
Q4
$579K Buy
+33,829
New +$637K ﹤0.01% 4925

Other funds holding RXRX

Israel Englander's RXRX Position: Q2 2026 in Review

Israel Englander reduced its Recursion Pharmaceuticals (RXRX) stake by 30% in Q2 2026, selling an estimated $2.59M and leaving 1,834,762 shares worth $6.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Israel Englander first reported a position in RXRX in Q4 2021 and has held it in 15 quarters since. The position peaked at $8.02M in Q1 2026. 339 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Israel Englander held 1,834,762 shares of Recursion Pharmaceuticals worth $6.73M as of Q2 2026.
  • Israel Englander sold 777,515 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.59M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2707 holding.
  • Israel Englander first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Israel Englander's Recursion Pharmaceuticals position peaked at $8.02M in Q1 2026.
  • 339 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.